Ketorolac

證據等級: L5

預測適應症: 3 個

Ketorolac: From Acute Pain to Headache Disorder

One-Sentence Summary

Ketorolac is a potent parenteral non-steroidal anti-inflammatory drug (NSAID), widely used in clinical practice for the short-term management of moderate to severe acute pain. The TxGNN model predicts it may be effective for Headache Disorder (encompassing migraine and tension-type headache), with 36 clinical trials and 19 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not registered in the Philippines (no approved indication on record)
Predicted New Indication	Headache Disorder
TxGNN Prediction Score	99.43%
Evidence Level	L1
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Ketorolac is a COX-1/COX-2 inhibitor belonging to the pyrrolo-pyrrole NSAID class. It works by blocking cyclooxygenase enzymes, which reduces the synthesis of prostaglandins — key chemical messengers involved in pain sensitization, inflammation, and vasodilation.

Prostaglandins play a central role in the pathophysiology of both migraine and tension-type headache. In migraine, prostaglandin E2 (PGE2) activates and sensitizes trigeminal nociceptors, contributing to the characteristic unilateral throbbing pain and associated photophobia and phonophobia. Ketorolac’s potent inhibition of prostaglandin synthesis — combined with its parenteral availability for rapid-onset delivery — makes it mechanistically well-suited for aborting acute headache attacks, particularly in emergency department settings where oral medications cannot be used.

Clinically, Ketorolac has been deployed as a first-line or comparator agent for acute migraine and tension-type headache since the early 1990s. Its inclusion as the active “standard care” arm in multiple Phase 3 and Phase 4 randomized trials confirms its de facto role in headache management, giving the TxGNN prediction strong empirical grounding beyond model scoring alone.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01267864	Phase 4	Completed	330	Head-to-head RCT comparing IV valproate, IV metoclopramide, and IV ketorolac for acute migraine in the ED
NCT01011673	Phase 4	Completed	123	Ketorolac vs metoclopramide/diphenhydramine for acute tension-type headache in the ED
NCT01596166	Phase 4	Completed	56	IV ketorolac + metoclopramide combination for pediatric migraine in the emergency department
NCT02358681	Phase 3	Completed	59	Non-inferiority trial of intranasal vs IV ketorolac for acute migraine in children
NCT00483717	Phase 2	Completed	173	Double-blind placebo-controlled study of intranasal ketorolac for acute migraine — safety and efficacy
NCT01807234	Phase 4	Completed	72	Ketorolac nasal spray vs sumatriptan nasal spray vs placebo for acute migraine abortive therapy
NCT03081416	Phase 3	Completed	80	THINK Trial: intranasal ketamine vs standard care (ketorolac) for acute headache in the ED
NCT03221569	Phase 4	Unknown	60	Sub-dissociative ketamine vs ketorolac for acute tension-type headache in the ED
NCT02664116	Phase 4	Unknown	40	IM ketorolac vs oral diclofenac potassium powder (Cambia) for acute severe migraine
NCT05983354	NA	Unknown	55	Pilot RCT comparing oral vs parenteral ketorolac + metoclopramide for acute migraine in the ED

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35138658	2022	Meta-analysis	Acad Emerg Med	Systematic review and meta-analysis confirming efficacy of parenteral ketorolac in treating acute migraine headache
39674934	2025	Meta-analysis	Ann Emerg Med	Bayesian network meta-analysis ranking the relative effectiveness and safety of pharmacologic therapies for migraine in the ED
41321235	2026	Guideline	Headache	2025 AHS guideline update on parenteral pharmacotherapies for acute migraine management in the ED — includes ketorolac recommendations
35670115	2022	RCT	Headache	Randomized trial assessing efficacy and safety of IV metoclopramide alone vs with add-on IV ketorolac for pediatric migraine in the ED
30783794	2019	RCT	Neurol Sci	Prospective double-blind RCT comparing ketorolac 30 mg, dexamethasone, metoclopramide, and chlorpromazine IV for migraine pain relief and recurrence prevention
1514724	1992	RCT	Ann Emerg Med	Landmark early RCT: IM ketorolac vs meperidine/hydroxyzine for acute migraine in the ED
37849443	2024	Meta-analysis	Adv Clin Exp Med	Updated systematic review and meta-analysis comparing IV ketorolac vs IV metoclopramide in adult migraine patients
25600718	2015	Review	Headache	American Headache Society updated evidence assessment of pharmacological therapies for acute migraine, including ketorolac
24875925	2015	Review	Cephalalgia	Canadian Headache Society systematic review and recommendations on migraine pain management in emergency settings
37291500	2023	Meta-analysis	BMC Neurol	Network meta-analysis of randomized controlled trials comparing metoclopramide and other antimigraine drugs (including ketorolac) for acute attacks

Philippines Market Information

Ketorolac is currently not registered in the Philippines. No product authorizations were found in the regulatory database.

Safety Considerations

Please refer to the package insert for safety information.

Note: A notable drug interaction has been documented in the literature (PMID 7928331): co-administration of ketorolac with lithium (used in cluster headache prophylaxis) has been associated with lithium neurotoxicity. Clinicians should exercise caution when using ketorolac in patients on lithium therapy.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 and Phase 4 RCTs, corroborated by recent meta-analyses and 2025–2026 clinical practice guidelines from major headache societies, establish ketorolac as an evidence-based treatment for acute headache disorders. This is one of the highest-confidence TxGNN predictions reviewable — the clinical evidence substantially predates and independently validates the model output. The primary barrier to Philippines deployment is the absence of local registration, not a lack of efficacy evidence.

To proceed, the following is needed:

Philippines FDA Registration: Submit a product registration dossier (no licenses currently on record); identify a local marketing authorization holder or distributor
Package Insert Review: Obtain and parse the full package insert to document black-box warnings, contraindications (e.g., renal impairment, peri-operative CABG use, active peptic ulcer disease), and duration-of-use restrictions (ketorolac is typically limited to ≤5 days in most regulatory labels due to cumulative GI and renal toxicity risk)
Formulation Decision: Confirm target route of administration — parenteral (IV/IM) formulations carry the strongest evidence base; intranasal formulations (e.g., Sprix®) show promise but with a smaller evidence body
Drug Interaction Screening: Establish a pharmacovigilance protocol for high-risk combinations, particularly with lithium, anticoagulants, and other NSAIDs
Risk Management Plan: Define appropriate patient selection criteria, monitoring parameters (renal function, GI symptoms), and maximum treatment duration for local prescribing guidelines
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.